FiercePharmaOriginal article
{"a":[{"_":"Sandoz strikes $322M biosimilars deal with Shanghai Henlius ","$":{"href":"/pharma/sandoz-strikes-322m-biosimilars-deal-shanghai-henlius","hreflang":"en"}}]}
PartnershipPositive
AI Analysis
Summary
Sandoz has entered into a partnership with Shanghai Henlius to acquire commercialization rights to three early-stage biosimilars, with upfront payments of $100.5 million and potential milestone payments reaching a total deal value of $322 million.
Outcome Details
Commercialization rights agreement for three biosimilars in early development
Importance:7/10
Sentiment:
0.60
biosimilarspartnershiplicensingcommercialization rights
Related Companies
Read the original article
Published by FiercePharma on August 17, 2026 10:50 AM